Please use this identifier to cite or link to this item:
Title: Epigenetic-based treatment as a potential strategy to treat Friedreich’s ataxia
Authors: Grech, Alfred
Baldacchino, Alexandra
Keywords: Friedreich's ataxia
Nervous system -- Diseases -- Treatment
Nervous system -- Degeneration
Issue Date: 2013
Publisher: Medical Portals Ltd.
Citation: Grech, A. & Baldacchino, A. (2013). Epigenetic-based treatment as a potential strategy to treat Friedreich’s ataxia. The Synapse, (5), 10-12
Abstract: Friedreich’s ataxia (FRDA) is an autosomal recessive neurodegenerative disorder. It is the most common inherited ataxia in Europe. The neurodegeneration is progressive and normally, within 15-20 years, the patient becomes wheel-chair bound, and ultimately, is totally incapacitated. Affected individuals normally succumb from heart complications. Frataxin (FXN) is a mitochondrial protein that is deficient in FRDA. The deficiency is caused by a mutation within the first intron of the FXN gene which codes for frataxin. Epigenetic mechanisms are responsible in FRDA and epigenetic-based treatment is a potential new strategy to treat FRDA.
Appears in Collections:The Synapse, Issue 5
The Synapse, Issue 5

Files in This Item:
File Description SizeFormat 
Epigenetic-based treatment.pdf949.46 kBAdobe PDFView/Open

Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.